Mutant TP53 hijacks RNA-splicing factor RBM28 to suppress double-stranded RNA triggered antitumor immunity
Open Access
- 25 August 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10165
Abstract
TP53 mutation may not only compromise its multifaceted tumor-suppressive functions but also confer oncogenic properties. Here, we demonstrate that DNA-binding domain mutations of TP53 unexpectedly confer a transcriptional regulatory function, directly driving RNA-splicing factor RBM28 overexpression. Overexpressed RBM28 excessively splices transposon elements, inhibiting double-stranded RNA (dsRNA) formation, thereby suppressing dsRNA-triggered type I interferon (IFN) signaling and subsequent anti-tumor immunity. We demonstrate in mouse tumorigenesis models and human multi-stage esophageal cancer development that mutant p53 (mutp53)-driven aberrant RBM28/dsRNA/IFN axis plays a crucial role in cancer initiation, progression and resistance to immune checkpoint blockade (ICB) therapy through innate immune suppression. Pan-cancer analysis indicates that this mechanism underlies ICB resistance in most cancers. Pharmacological restoration of normal p53 conformation or targeted RNA-splicing inhibition enhances anti-tumor immunity and ICB efficacy. Collectively, our study has unveiled an important function of mutp53 in establishing immunosuppressive tumor microenvironment, which provides an actionable framework for intervention and therapy in TP53-mutated cancers.Keywords
Funding Information
- Medical and Health Technology Innovation Project of Chinese Academy of Medical Sciences
This publication has 90 references indexed in Scilit:
- LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinomaGut, 2014
- The Yeast Ski Complex: Crystal Structure and RNA Channeling to the Exosome ComplexCell, 2013
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate CancerJournal of Clinical Oncology, 2012
- Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticityCell Cycle, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Alopecia, Neurological Defects, and Endocrinopathy Syndrome Caused by Decreased Expression of RBM28, a Nucleolar Protein Associated with Ribosome BiogenesisThe American Journal of Human Genetics, 2008
- Human RBM28 protein is a specific nucleolar component of the spliceosomal snRNPsBiological Chemistry, 2006
- Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiationCancer, 2005
- Manipulation of Alternative Splicing by a Newly Developed Inhibitor of ClksJournal of Biological Chemistry, 2004
- Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated MiceClinical Cancer Research, 2004